Literature DB >> 22419652

Racial/ethnic differences in treatment discussed, preferred, and received for prostate cancer in a tri-ethnic population.

G M Monawar Hosain1, Maureen Sanderson, Xianglin L Du, Wenyaw Chan, Sara S Strom.   

Abstract

This study was conducted to explore whether racial/ethnic differences exist in treatment discussed, preferred, and ultimately received for localized prostate cancer (PCa) as epidemiological data are scant on this issue. The authors recruited 640 localized PCa patients from the Texas Medical Center, Houston, Texas, between 1996 and 2004. The authors used a structured questionnaire to collect data through personal interviews. Three main treatment modalities for localized PCa, consisting of surgery, radiation therapy, and watchful waiting, were considered for this study. It was found that health professionals were less likely to discuss surgery (odds ratio [OR] = 0.35, 95% confidence interval [CI] = 0.18-0.68) and watchful waiting (OR = 0.53, 95% CI = 0.34-0.83) with Hispanics than Whites. However, African Americans were less likely to receive watchful waiting (OR = 0.22, 95% CI = 0.05-0.93). They were more likely to prefer (OR = 1.23, 95% CI = 0.78-1.94) and receive (OR = 1.27, 95% CI = 0.87-1.86) radiation therapy, although they did not achieve statistical significance (p < .05). Higher age was associated with lower likelihood of discussing, preferring, and receiving surgical treatment. Higher Gleason sum was associated with lower likelihood of discussing treatment. A comparison of concordances between treatment preferred by patients and what was actually received, in general, showed a higher agreement for surgery and radiation therapy. More exploration needs to be done in other settings to confirm these findings.

Entities:  

Mesh:

Year:  2012        PMID: 22419652      PMCID: PMC3368001          DOI: 10.1177/1557988311432467

Source DB:  PubMed          Journal:  Am J Mens Health        ISSN: 1557-9883


  34 in total

Review 1.  Racial and ethnic disparities in the receipt of cancer treatment.

Authors:  Vickie L Shavers; Martin L Brown
Journal:  J Natl Cancer Inst       Date:  2002-03-06       Impact factor: 13.506

2.  Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States).

Authors:  C R Morris; K P Snipes; R Schlag; W E Wright
Journal:  Cancer Causes Control       Date:  1999-12       Impact factor: 2.506

Review 3.  The role of health literacy in patient-physician communication.

Authors:  Mark V Williams; Terry Davis; Ruth M Parker; Barry D Weiss
Journal:  Fam Med       Date:  2002-05       Impact factor: 1.756

4.  Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.

Authors:  Stephen A Boorjian; R Jeffrey Karnes; Rosalia Viterbo; Laureano J Rangel; Eric J Bergstralh; Eric M Horwitz; Michael L Blute; Mark K Buyyounouski
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

5.  Perceptions of cancer in an African-American community: a focus group report.

Authors:  Sharada Shankar; Elizabeth Selvin; Anthony J Alberg
Journal:  Ethn Dis       Date:  2002       Impact factor: 1.847

6.  Making decisions about treatment for localized prostate cancer.

Authors:  S K Steginga; S Occhipinti; R A Gardiner; J Yaxley; P Heathcote
Journal:  BJU Int       Date:  2002-02       Impact factor: 5.588

7.  The effect of patient race and socio-economic status on physicians' perceptions of patients.

Authors:  M van Ryn; J Burke
Journal:  Soc Sci Med       Date:  2000-03       Impact factor: 4.634

8.  Doctor-patient communication and cancer patients' quality of life and satisfaction.

Authors:  L M Ong; M R Visser; F B Lammes; J C de Haes
Journal:  Patient Educ Couns       Date:  2000-09

9.  Radical prostatectomy: geographic and demographic variation.

Authors:  S Lai; H Lai; A Krongrad; S Lamm; J Schwade; B A Roos
Journal:  Urology       Date:  2000-07       Impact factor: 2.649

10.  Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study.

Authors:  Richard M Hoffman; Linda C Harlan; Carrie N Klabunde; Frank D Gilliland; Robert A Stephenson; William C Hunt; Arnold L Potosky
Journal:  J Gen Intern Med       Date:  2003-10       Impact factor: 5.128

View more
  8 in total

1.  Toward ethically responsible choice architecture in prostate cancer treatment decision-making.

Authors:  J S Blumenthal-Barby; Denise Lee; Robert J Volk
Journal:  CA Cancer J Clin       Date:  2015-05-21       Impact factor: 508.702

2.  Differences in the Severity, Distress, Interference, and Frequency on Cancer-Related Symptoms Between Island Hispanic Puerto Ricans and Mainland Non-Hispanic Whites.

Authors:  Velda J González-Mercado; Leorey N Saligan; Ming Ji; Maureen Groer; Elsa Pedro; Susan McMillan
Journal:  J Immigr Minor Health       Date:  2018-08

3.  National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer.

Authors:  Adam B Weiner; Oliver S Ko; Alec Zhu; Daniel E Spratt; Jim C Hu; Edward M Schaeffer
Journal:  Urol Oncol       Date:  2019-01-02       Impact factor: 3.498

4.  Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer.

Authors:  Yu Liu; Ingrid J Hall; Christopher Filson; David H Howard
Journal:  Urol Oncol       Date:  2020-12-09       Impact factor: 2.954

5.  Racial and Ethnic Differences in Prostate Cancer Survivors' Perceived Engagement in Treatment Decision-Making.

Authors:  Nynikka R Palmer; Steven E Gregorich; Jennifer Livaudais-Toman; Jane Jih; Celia P Kaplan
Journal:  J Racial Ethn Health Disparities       Date:  2018-03-07

6.  Are cancer-related decision aids appropriate for socially disadvantaged patients? A systematic review of US randomized controlled trials.

Authors:  Kimberly R Enard; Patricia Dolan Mullen; Geetanjali R Kamath; Nickell M Dixon; Robert J Volk
Journal:  BMC Med Inform Decis Mak       Date:  2016-06-06       Impact factor: 2.796

7.  Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital.

Authors:  Carolyn K Kan; Muhammad M Qureshi; Apar Gupta; Ankit Agarwal; Gretchen A Gignac; B Nicolas Bloch; Nicholas Thoreson; Ariel E Hirsch
Journal:  Adv Radiat Oncol       Date:  2017-12-13

8.  The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD.

Authors:  Joel E Pacyna; Simon Kim; Kathleen Yost; Hillary Sedlacek; Daniel Petereit; Judith Kaur; Bruce Rapkin; Robert Grubb; Electra Paskett; George J Chang; Jeff Sloan; Ethan Basch; Brittny Major; Paul Novotny; John Taylor; Jan Buckner; J Kellogg Parsons; Michael Morris; Jon C Tilburt
Journal:  BMC Cancer       Date:  2018-08-06       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.